Business Blockbuster - Helpng business to be more visible on Google

Daily Bulletin

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

  • Written by: PR Newswire Asia - Daily Bulletin Au RSS
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights:

  • Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis
  • Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulatory and commercial benefits
  • Positions Neurizon to advance the development of NUZ-001 for patients facing ALS, a debilitating neurodegenerative disease with limited treatment options

MELBOURNE, Australia, Nov. 11, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce it has received notice of a positive opinion from the European Medicines Agency (EMA) for Orphan Medicinal Product Designation (OMPD) following its application for its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The European Commission is scheduled to issue the official decision on the Orphan Designation in December.

OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced regulatory fees, free protocol assistance, and, importantly, 10 years of market exclusivity in the European Union (EU). During the exclusivity period, the EMA and the EU Member States will not accept another marketing authorisation application for a similar medicinal product in the same therapeutic indication.

Neurizon is advancing NUZ-001 through a Phase 2/3 clinical study as part of the HEALEY ALS Platform Trial, with patient enrolment expected to commence in early H1 CY2025. Our protocol regimen has been designed to support the potential for early regulatory approval. The notice of a positive opinion from the EMA on the OMPD further supports our pathway for NUZ-001, underscoring its potential to meet urgent unmet needs in ALS on a global scale.

Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "Receiving a positive opinion from the EMA for Orphan Medicinal Product Designation is a critical milestone for Neurizon. The prevalence in the EU is double that of the United States.[1] With the OMPD, along with the Orphan Drug Designation from the United States Food and Drug Administration, we have secured market exclusivity for NUZ-001 across the world's key markets for the treatment of ALS. This important recognition highlights the significant potential of NUZ-001 to provide a meaningful therapeutic option for patients with ALS while building the commercial value of this promising candidate. We look forward to further engagement with the EMA and other regulators as we advance our mission to deliver innovative treatments to patients battling this devastating disease."

Next Steps:

  • A formal decision from the European Commission is scheduled for December 2024.
  • Continue regulatory engagement with the EMA and the United States Food and Drug Administration to support the clinical development pathway of NUZ-001.
  • Finalise preparations for the Phase 2/3 clinical study through the prestigious HEALEY ALS Platform Trial, in alignment with the Company's strategic focus on neurodegenerative diseases.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Dr. Michael ThurnManaging Director and Chief Executive OfficerNeurizon Therapeutics Limitedenquiries@neurizon.com

+61 (3) 9692 7222

About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

[1] Park J, Kim J-E and Song T-J (2022) The Global Burden of Motor Neuron Disease: An Analysis of the 2019 Global Burden of Disease Study. Front. Neurol. 13:864339. doi: 10.3389/fneur.2022.864339

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please visit https://investorhub.neurizon.com

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/4552807_CN52807_0

Business News

The Growing Demand for Durable Plastic Packaging Supplies Across Australia

Why Do Australian Businesses Need Reliable Plastic Packaging Supplies? Businesses need packaging that can withstand everyday handling, storage, and distribution without creating avoidable delays. Pla...

Daily Bulletin - avatar Daily Bulletin

Office Cleaning Melbourne: Choosing the Right Scope for Your Office

A well-planned office cleaning Melbourne arrangement starts with a clear understanding of the premises and the people who use it. An office may include private work areas, shared desks, reception, mee...

Daily Bulletin - avatar Daily Bulletin

How Businesses Can Prepare for Unexpected Power Outages

Power failures can occur quickly. The supply may be interrupted by bad weather, issues with the electricity network, damaged equipment or local construction work. This can be just a hassle for a fam...

Daily Bulletin - avatar Daily Bulletin

How Chatswood Tutoring Can Fit Into a Student’s Weekly Routine

Create a Predictable Weekly Structure A consistent weekly routine can make study easier to manage when students are balancing several subjects. Chatswood tutoring can provide a fixed learning point a...

Daily Bulletin - avatar Daily Bulletin

The Rise of Digital Marketplaces in the Australian Trade Sector

For decades, the Australian trade and construction sector operated almost entirely on word-of-mouth recommendations and local community networks. Small business owners typically relied on local newspa...

Daily Bulletin - avatar Daily Bulletin

How Immigration Lawyers Can Help

Introduction Visa decisions can shape employment, family life, study plans, travel, and future residence. A small omission can lead to delay, added expense, or refusal. Immigration lawyers assess l...

Daily Bulletin - avatar Daily Bulletin

How Industrial Drying Equipment Supports Efficient Processing

Many industrial processes require moisture to be removed from compressed air, products or process materials before they move to the next stage. Excess moisture can affect equipment performance, produc...

Daily Bulletin - avatar Daily Bulletin

Practical Ways a Whiteboard Can Improve Workplace Communication

Effective communication helps teams stay organised, share ideas and keep track of important information. While digital tools are now common in many workplaces, a whiteboard continues to provide a simp...

Daily Bulletin - avatar Daily Bulletin

Designing Eco-Friendly Custom Water Bottles for Your Next Event

The Evolution of Sustainable Event Merchandise Event planning has undergone a massive transformation over the last decade. Gone are the days when organizers could hand out cheap, single use plastic...

Daily Bulletin - avatar Daily Bulletin

The Daily Magazine

How Much Life Does Your Roof Have Left? Recognizing When Replacement Becomes Necessary

A roof can age quietly for years. From the street, everything may look reassuringly ordinary, even w...

How Australian Drivers Can Make Their Cars Harder to Steal

Most people don't think much about car theft until it happens to them, or to someone they know. Th...

The Short-Term Rental Rules Australian Owners Can’t Afford to Guess At

A holiday let looks simple from the outside: a spare property, a listing, some guests. Underneath ...

The Risks Of Removing Ear Wax Without Professional Guidance

Ear wax is an essential component of the hygiene process since it acts as a barrier between the ea...

Plumbing Call-Out Fees in Perth Explained

When you hire a plumber to fix a problem with a dripping tap, leaking pipe, or whatever it might be...

Workshop Tool Maintenance: A Practical Guide to Drills, Sanders and Table Saws

A drill that strips every screw head. A sander that leaves swirl marks however long you work the pan...

How Architecture and Engineering Firms Can Improve Project Profitability

Project profitability remains one of the most persistent challenges for architecture and engineering...

The Blossoming World of Fresh Flower Delivery: An In-Depth Exploration

In recent years, the demand for fresh flower delivery in Sydney has soared, driven in part by the ...

How Penrith SMEs Can Keep Stock and Equipment Working for the Business

For Penrith SMEs in 2026, efficient inventory starts with reliable stock data: what is on hand, wher...